$XBI $67.61 | +5.67%
Table of Contents:
Covid Updates
#MRNA +5.7% Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
Pipeline Updates
#CLVS +31.9% (6/14) Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
#SESN +29.2% Sesen Bio no longer seeks reverse stock split as route to regain compliance with Nasdaq
#ALT +22.9% Altimmune Announces Oral Presentation Of Pemvidutide Clinical Data At Upcoming EASL International Liver Congress™ On June 25, 2022.
#PHVS +22.1%
#SANA +21.5% Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates.
#LYEL +20%
#SRRK +10.9% Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA).
#CDXS +8.4% Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides.
#RNA +7.8% Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program.
#MYOV +7.7% Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain.
#NVAX +6.9% Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022.
#CYTK +2.4% Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil.
#CYCN +0.2% Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease.
#SRRA -0.1% Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration.
#OBSV -1.6% ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
#LVTX -13.5% (6/16) LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients
#IPHA -14.5%
#EQ -16.7%
#IMV -21.8%
#AXLA -22.8%
#ADXN -55.2% Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate.
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#AKRO +17.3% (6/16) Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
#SRRK +10.9% Scholar Rock Announces $205 Million Registered Direct Offering.
#SEEL +5.7% NEALS Webinar (Fri 6/17) at 5pm to Discuss Seelos' SLS-005 in the Healey ALS Platform Trial.
Posted by DV/FS
Comments